CTOs on the Move

Kindeva Drug Delivery

www.kindevadd.com

 
Kindeva is a global force in combination drug delivery and manufacturing. Leveraging more than 100 years of innovation, Kindeva provides unrivaled expertise at every stage of pulmonary & nasal, injectable, and transdermal therapy development and manufacturing. Whether determining ideal delivery and dosage or scaling sterile manufacturing and fill-finish operations, every solution is backed by extensive technological capabilities, deep regulatory knowledge, and nine state-of-the-art facilities. Kindeva`s proactive, informed solutions minimize risk and maximize confidence from ideation through commercialization, bringing high-quality products to patients in need, faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Shanmugasundaram Sathish
VP, Digital and Enterprise Applications Profile
Marjorie Nehring
Associate Director of Information Technology - Quality and Manufacturing Applications Profile

Similar Companies

Nevakar

Nevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.

Emendo Biotherapeutics

Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.

PBN Pharma

PBN Pharma is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boehringer Laboratories

Boehringer Laboratories, LLC. is a family owned American medical technology company with headquarters in Phoenixville, Pennsylvania.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.